IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Receipt

In re Patent Application of

ANTONSSON et al

Serial No. 10/074,008

Filed: February 14, 2002

For: NOVEL COMPOUNDS

Atty. Ref.:

3764-116

Group:

Examiner:

TECHCENTER 1800/20

April 25, 2002

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231

Sir:

į

RECEIVED

MAY 0 3 2002

TECH CENTER 1600/20

REQUEST FOR CORRECTION OF FILING RECEIPT

Enclosed is a copy of the Filing Receipt for the above-identified application which incorrectly lists three priority documents and one PCT application. Under the heading "Foreign Applications" please delete the following: Sweden 9704542-1 12/05/1997; Sweden 9801989-6 06/04/1998; PCT/SE98/02191 12/01/1998." The corrections are shown in red on the attached copy of the filing receipt. Please note your records accordingly. Correction of same is respectfully requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

egnard C. Mitchard Reg. No. 29,009

LCM:lks 1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100





COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/074,008	02/14/2002	1653	1298	3764-116		51	1

CONFIRMATION NO. 7998

FILING RECEIPT

OC000000007835522

NIXON & VANDERHYE P.C. 8th Floor 1100 North Glebe Road Arlington, VA 22201-4714

Date Mailed: 04/10/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE. NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will TECH CENTER 1600/2900 generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Thomas Antonsson, Lindome, SWEDEN: David Gustafsson, Kullavik, SWEDEN; Kurt-Jurgen Hoffmann, Kullavik, SWEDEN; Jan-Erik Nystrom, Lindome, SWEDEN; Henrik Sorensen, Molnlycke, SWEDEN: Mikael Sellen, Goteborg, SWEDEN;



AstraZeneca AB:

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/708,449 11/09/2000 WHICH IS A CON OF 09/353,644 07/15/1999 PAT 6,262,028 WHICH IS A CON OF 08/776,231 01/31/1997 PAT 5,965,692 WHICH IS A 371 OF PCT/SE96/01680 12/17/1996

Foreign Applications

UNITED KINGDOM 9526273.9 12/21/1995 SWEDEN 9600556-6 02/15/1996 -SWEDEN-9704542-1-12/05/1997 SWEDEN 9801989-6-06/04/1998 PCT/SE98/02191 12/01/1998

If Required, Foreign Filing License Granted 04/08/2002

Projected Publication Date: 07/18/2002

Non-Publication Request: No

Early Publication Request: No

APR 2 5 2002

Title

Prodrugs of thrombin inhibitors

Preliminary Class

514

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).